OVERVALUEDNASDAQ · Healthcare

Insight Molecular Diagnostics Inc.

IMDX

FAIR PRICE VALUATION

44.7%downside

Updated daily

Model: DCF 50% · Relative 30% · Consensus 20%

MARKET PRICE

$3.08

FAIR PRICE

$1.70

MARGIN

$1.38

UNDERVALUEDFAIROVERVALUED

P/E Ratio

N/A

Div. Yield

N/A

ROE

684.6%

Exceptional

Market Cap

$88M

Small-cap

COMING SOON

Get notified when IMDX's fair price changes

Fair Price Index app is launching soon with push notifications when valuations shift for stocks you follow.

iOS and Android · Free tier available

KEY FACTS

CEO

Joshua Riggs

COUNTRY

US

HEADQUARTERS

Nashville

SECTOR

Healthcare

EXCHANGE

NASDAQ

METHODOLOGY

How we calculate IMDX's fair price

Insight Molecular Diagnostics Inc.'s fair price of $1.70 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $3.08, IMDX trades 44.7% above its calculated fair value.

DCF MODEL · 50%

Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting IMDX's risk profile.

RELATIVE · 30%

Comparing IMDX's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.

ANALYST · 20%

Aggregated analyst price targets for IMDX, weighted by recency and analyst accuracy.

TRY IT YOURSELF

Want to test your own assumptions? Use our free calculators to estimate IMDX's fair value with your own inputs.

LEARN MORE

Bulios

POWERED BY BULIOS

Get full analysis, financials, and AI insights for IMDX.

Explore on Bulios

FAQ

What is the fair price of IMDX?+

Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Insight Molecular Diagnostics Inc. is $1.70. At the current market price of $3.08, IMDX trades 44.7% above its calculated fair value.

Is IMDX overvalued or undervalued?+

Insight Molecular Diagnostics Inc. is currently overvalued based on our valuation model. The stock trades at $3.08, which is 44.7% above the fair price of $1.70.

How often is IMDX's fair price updated?+

We update fair price calculations for IMDX daily after market close. The current fair price of $1.70 incorporates the latest market data and sector multiples.

What factors affect IMDX's fair price calculation?+

IMDX's fair price of $1.70 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of 684.6%.

Is IMDX a good buy right now?+

At $3.08, IMDX trades 44.7% above our fair value estimate of $1.70. The stock is currently overvalued. ROE stands at 684.6% (exceptional). Fair Price Index provides valuation data — always do your own research before investing.

Does IMDX pay dividends?+

IMDX does not currently pay a dividend.

RELATED STOCKS

Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.